Jansitin Duo

Metformin Hydrochloride and Sitagliptin, the active ingredients in Jansitin Duo, are a Biguanide and DPP‑4 inhibitor presented as an oral tablet formulation for systemic use. They are indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels when used with diet and exercise.

GNH USA supplies Jansitin Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Jansitin Duo combines metformin and sitagliptin to improve glycemic control in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. - Inadequate control with metformin alone: adds DPP‑4 inhibition to achieve better overall glycaemic reduction. - Adjunct to diet and exercise in type 2 diabetes: assists patients in reaching individualized HbA1c targets.

The combination may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, usually transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache. - Upper respiratory tract infection: nasopharyngitis symptoms. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic complication. - Acute pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypersensitivity reactions: including skin rash, angioedema, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Hypoglycaemia (when combined with other glucose‑lowering agents): symptomatic low blood sugar.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic impairment: use with caution; monitor liver enzymes. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia or tissue hypoperfusion. - Pregnancy and lactation: consult a healthcare professional before use. - Drug interactions: review concomitant medications for potential effects on glucose control. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Jansitin Duo may interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Insulin secretagogues (e.g., sulfonylureas): increased risk of hypoglycaemia. - Iodinated contrast agents in patients with renal dysfunction: heightened risk of metformin‑associated lactic acidosis. - Strong CYP3A4 inhibitors (rarely affecting sitagliptin): may raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Cimetidine: can increase sitagliptin concentrations. - Diuretics (especially thiazides): may affect renal clearance of metformin. - ACE inhibitors or ARBs: combined use may increase risk of renal impairment and lactic acidosis. - Alcohol: excessive intake can potentiate metformin‑related lactic acidosis. - Beta‑blockers: may mask hypoglycaemia symptoms.